Answers are grounded in this paper and cite their sources.
Among patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was associated with weight gain, possibly reflecting withdrawal of the inhibitory effect of higher efavirenz concentrations on weight gain. The difference by concomitant nucleoside analogue is unexplained.
No takes yet. Share an insight, caveat, or question.
Leonard et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: